SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

September 19, 2013 09:00 ET

Elsevier Business Intelligence Releases the Top BioPharma Projects to Watch List

BEDMINSTER, NJ--(Marketwired - Sep 19, 2013) - Elsevier Business Intelligence announces the 2013 Top Projects to Watch and the companies confirmed to present at Therapeutic Area Partnerships (TAP) being held at Hyatt Regency in Boston from November 18th - 20th.

Every year, TAP's expert clinical advisory panels hand select the top 10 projects chosen to present in each major therapeutic area (Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, and Advanced Therapies which includes Gene Therapy, Cell Therapy, Stem Cell Therapy, Rare Diseases and other high value and niche areas) based on the likelihood of their success as future products.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said David Cassak, Vice President, Content, Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers."

Visit the website often, as the list of Top Projects to Watch will be updated frequently.

TAP has become a springboard to success for many companies. Numerous presenting companies in previous years have gone on to establish major partnerships or been acquired. Among recent Top 10 picks, both Optimer Pharmaceuticals and Trius Therapeutics, from the Infectious Diseases track, were acquired by Cubist Pharmaceuticals; AstraZeneca purchased Pearl Therapeutics, which presented in the Anti-Inflammatory/Autoimmune Diseases track; and Novartis licensed development rights to Enanta Pharmaceuticals' hepatitis C virus drug. Numerous oncology Top 10 picks have out-licensed assets or been acquired, including Avila Therapeutics, purchased by Celgene Corporation.

Through Therapeutic Area Partnership's premier partnering system, attendees will have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Valuable networking opportunities from casual gatherings to one-on-one partnering meetings bring together top-level peers from around the globe to make this one of the industry's most productive events.

This year's agenda promises to deliver expert analysis of trends and opportunities in licensing and deal making, information on emerging biomedical opportunities, strategies for leading, financing and partnering, insights into fast-changing therapeutic areas and more!

Join this uniquely focused and highly productive meeting among business development and R&D leadership to improve the partnering process and encourage innovative thinking about productivity and deal making. Attend TAP this year and walk away with real opportunities for lucrative acquisitions and alliances. For more information or to register, visit

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit:

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information

  • Media contact:
    Mike Fergus
    Elsevier Business Intelligence
    +1 908 748 1185
    Email Contact